Jag Capital Management LLC Acquires Shares of 16,569 Thermo Fisher Scientific Inc. $TMO

Posted by Brenda Bartman on Jul 17th, 2026

Jag Capital Management LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 16,569 shares of the medical research company’s stock, valued at approximately $8,144,000. Thermo Fisher Scientific accounts for about 0.9% of Jag Capital Management LLC’s investment portfolio, making the stock its 29th biggest holding.

Several other hedge funds and other institutional investors also recently made changes to their positions in TMO. Assetmark Inc. boosted its holdings in shares of Thermo Fisher Scientific by 22.9% in the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after buying an additional 7,023 shares during the last quarter. North Dakota State Investment Board purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $7,505,000. Confluence Investment Management LLC lifted its stake in Thermo Fisher Scientific by 14.2% in the fourth quarter. Confluence Investment Management LLC now owns 95,064 shares of the medical research company’s stock valued at $55,085,000 after purchasing an additional 11,841 shares during the last quarter. Argent Capital Management LLC increased its position in Thermo Fisher Scientific by 45.8% in the fourth quarter. Argent Capital Management LLC now owns 52,359 shares of the medical research company’s stock worth $30,340,000 after buying an additional 16,439 shares during the last quarter. Finally, Union Bancaire Privee UBP SA raised its stake in Thermo Fisher Scientific by 266.3% in the 4th quarter. Union Bancaire Privee UBP SA now owns 53,091 shares of the medical research company’s stock valued at $30,764,000 after acquiring an additional 38,597 shares during the period. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

TMO has been the subject of several analyst reports. Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. Morgan Stanley reiterated an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Stifel Nicolaus reduced their price objective on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Finally, Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $602.14.

Read Our Latest Report on TMO

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $544.03 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $403.36 and a fifty-two week high of $643.99. The firm’s fifty day moving average price is $483.22 and its 200-day moving average price is $514.76. The stock has a market cap of $202.17 billion, a P/E ratio of 29.91, a price-to-earnings-growth ratio of 2.37 and a beta of 0.87. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.